



## **Cosmo Pharmaceuticals announces expansion of agreement with Dr. Falk Pharma for Rifamycin SV MMX**

**Dublin, Ireland – 19 November 2020:** Cosmo Pharmaceuticals N.V. (SIX: COPN) announced today that it has expanded its existing license agreement with Dr. Falk Pharma GmbH (“Dr. Falk”) to include Rifamycin SV MMX in the new 600mg formulation currently tested in the IBS-D indication.

Under the agreement with Dr Falk, Cosmo will receive a further €2m down-payment plus reimbursement of a portion of the expenses borne for the development of the 600mg formulation plus a supply price which incorporates a high double-digit percentage of sales. Dr. Falk will also bear a portion of the future costs for the ongoing developments.

Rifamycin SV MMX 200mg is already approved in the US and EU for the treatment of travelers’ diarrhea and it is licensed to Dr. Falk for the EU and other countries and is marketed under the brand name Relafalk<sup>®</sup>, whereas it is licensed to RedHill BioPharma Ltd. (NASDAQ: RDHL) for the US where it is marketed under the brand name Aemcolo<sup>®</sup>. A Phase II clinical study with Rifamycin 600mg in IBS-D indication is currently ongoing and results are expected by year end.

Rifamycin SV MMX is a pharmaceutical product containing rifamycin SV formulated with Cosmo’s MMX<sup>®</sup> technology. Rifamycin SV MMX contains a broad spectrum, semi-synthetic, orally non-absorbable antibiotic. The application of MMX<sup>®</sup> technology to rifamycin SV allows the antibiotic to be delivered directly into the colon, avoiding unwanted effects on the beneficial bacterial flora living in the upper portions of the gastrointestinal tract.

Alessandro Della Chà, CEO of Cosmo, said: *“We are very pleased to expand our agreement with Dr. Falk with whom we have a long relationship. We look forward broadening the indications for this very important product”.*

### **About Cosmo Pharmaceuticals**

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device for use in colonoscopies and GI procedures. Cosmo has licensed Aemcolo<sup>®</sup> to Red Hill Biopharma Ltd. for the US and has licensed Relafalk<sup>®</sup> to Dr. Falk GmbH for the EU and other countries. For additional information on Cosmo and its products please visit the Company’s website: [www.cosmopharma.com](http://www.cosmopharma.com)

### **Financial calendar**

Jefferies, Virtual Healthcare Conference	November 17 – 19, 2020
Credit Suisse, Swiss EQ Mid Cap Conference	November 18 – 20, 2020

**Contact**

Niall Donnelly, CFO & Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

[ndonnelly@cosmopharma.com](mailto:ndonnelly@cosmopharma.com)

**Disclaimer**

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.